Thursday, July 9, 2026

Patent intelligence · US

US 11932695

Modified antibodies and related compounds, compositions and methods of use

granted A61KA61K47/54A61K47/545A61P
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 18
Applicant portfolio 1
Patent details — US 11932695
Jurisdiction
US
Status
granted
Grant date
Mar 19, 2024
Expiration
Mar 14, 2044
Claims
6
CPC classes
A61K, A61K47/54, A61K47/545, A61P
View on Google Patents ↗

Quick answer

US 11932695 (Modified antibodies and related compounds, compositions and methods of use) is held by Sensei Biotherapeutics, Inc.. Status: granted. Granted Mar 19, 2024. Expires Mar 14, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
6
CPC classes
A61K, A61K47/54, A61K47/545, A61P, A61P35/00

Frequently asked questions

What is US patent 11932695?

US 11932695 (Modified antibodies and related compounds, compositions and methods of use) is held by Sensei Biotherapeutics, Inc.. Status: granted. Granted Mar 19, 2024. Expires Mar 14, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11932695?

Sensei Biotherapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1 pharmaceutical patents for this assignee.

When does US 11932695 expire?

Our index shows an expiration date of Mar 14, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.